Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma / 中华血液学杂志

<p><b>OBJECTIVE</b>A prospective, multicenter and non-interventional prospective study was conducted to evaluate the clinical features of rituximab combined with chemotherapy (R-Chemo) as first-line treatment on newly diagnosed Chinese patients with diffuse large B-cell lymphoma (DLBCL).</p><p><b>METHODS</b>This was a single arm, prospective, observational multicenter and phase IV clinical trial for 279 patients, who were newly diagnosed as CD20-positive DLBCL from 24 medical centers in China 2011 and 2012, no special exclusion criteria were used. All patients received rituximab based R-Chemo regimes, such as R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone) and other regimes as the first-line treatment. The treatment strategies were determined by physicians and patients without detailed description for treatment course, dose, interval time and examination. Clinical response and safety of all patients were investigated in 120 days after completion of last dose of rituximab.</p><p><b>RESULTS</b>Of 279 patients, 258 with stage I-IV who received at least 1 cycle of rituximab treatment and completed at least one time of tumor assessment were enrolled into intention-to-treat analysis, including 148 male and 110 female. The median age of all patients was 57.2(12.8-88.4) years. ECOG performance statuses of 0 or 1 were observed in 91.1% of patients, international prognostic index levels in the low-risk and low-middle-risk groups in 76.4% of patients, the tumor diameters smaller than 7.5 cm in 69.0% of patients. All patients received 6 median cycles of R-Chemo treatment every 24.4 days. R-CHOP treatment was shown to improve the clinical response with overall response rates of 94.2%. Common adverse events included anemia, marrow failure, leukopenia, thrombocytopenia, digestive diseases, infection and liver toxicity. All adverse events are manageable.</p><p><b>CONCLUSION</b>Non-interventional clinical trial of R-Chemo remains the standard first-line treatment for newly diagnosed patients with DLBCL in real clinical practice, which is consistent with international treatment recommendations for DLBCL patients. R-Chemo can provide the clinical evidence and benefit as the first-line standard treatment for Chinese patients with DLBCL.</p>

Clinical features of 31 cases of angioimmunoblastic T-cell lymphoma / 中国肿瘤临床

Objective:To study the incidence, clinical features, diagnosis, and treatment of angioimmunoblastic T-cell Lymphoma (AITL). Methods:We retrospectively analyzed the clinical data of 31 patients with AITL treated in the tumor hospital of Harbin Medical University between January 1995 and January 2008. We also analyzed the incidence, clinical features, diagnosis, and treatment of AITL. Results:The complete response rate and partial response rate of the entire group were 54.8%and 16.1%, respectively. The overall response rate was 70.9%, and the median survival time was 27.3 months. The five-year survival rate of the entire group was 35%. The response rate was 76.5%in the CHOP group and 75%in the COP group. No significant differences were detected between two groups (P>0.05). Con-clusion:The symptoms and signs of ATIL differ in different sites. The COP and CHOP regimens have similar efficacy and tolerable side effects.

Design of security scheme of the radiotherapy planning administration system based on the hospital information system / 中华放射肿瘤学杂志

Objective To design a security scheme of radiotherapy planning administration system. Methods PowerBuilder 9i language was used to program the system through the model of client-server machine. Oracle 9i was used as the database server. Results In this system, user registration management, user login management, application-level functions of control, database access control, and audit trail were designed to provide system security. Conclusions As a prototype for the security analysis and protection of this scheme provides security of the system, application system, important data and message, which ensures the system work normally.

Clinical Observation of Carboplatin Combined with Poclitaxel in Treatment of NSCLCⅢb andⅣ / 中国药房

OBJECTIVE:To observe the therapeutic effect and adverse reactions of Carboplatin combined with Paclitaxel in treatment of NSCLC.METHODS:37patients with pathologically or cytologically proved NSCLCⅢb orⅣreceived treat?ment.Paclitaxel(150mg/m 2 )in saline iv drip for4-6h and Carboplatin(AUC6)iv drip alteratively administrated for21days.At least2therapeutic courses were carried out.RESULTS:Among37patients,3had complete remission,15partial re?mission13kept stable and6were progressive with a total effective rate of48.6%and one-year survival rate of51.3%.The common adverse reactions were muscular soreness and bone-marrow inhibition,however,most patients could tolerate the side effects.CONCLUSION:The therapeutic effect of Carboplatin and Paclitaxel on advanced NSCLC is reliable and the patients are tolerant of the side effects.